We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Tandem Diabetes (TNDM - Free Report) closed the most recent trading day at $63.76, moving +1.21% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.36%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.34%.
Coming into today, shares of the insulin pump maker had gained 1.84% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 gained 0.64%.
Investors will be hoping for strength from TNDM as it approaches its next earnings release. In that report, analysts expect TNDM to post earnings of -$0.28 per share. This would mark year-over-year growth of 72.82%. Meanwhile, our latest consensus estimate is calling for revenue of $50.32 million, up 84.44% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.72 per share and revenue of $264.27 million, which would represent changes of +71.76% and +43.73%, respectively, from the prior year.
Any recent changes to analyst estimates for TNDM should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.15% higher within the past month. TNDM is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know
Tandem Diabetes (TNDM - Free Report) closed the most recent trading day at $63.76, moving +1.21% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.36%. Meanwhile, the Dow gained 0.36%, and the Nasdaq, a tech-heavy index, added 0.34%.
Coming into today, shares of the insulin pump maker had gained 1.84% in the past month. In that same time, the Medical sector lost 0.3%, while the S&P 500 gained 0.64%.
Investors will be hoping for strength from TNDM as it approaches its next earnings release. In that report, analysts expect TNDM to post earnings of -$0.28 per share. This would mark year-over-year growth of 72.82%. Meanwhile, our latest consensus estimate is calling for revenue of $50.32 million, up 84.44% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.72 per share and revenue of $264.27 million, which would represent changes of +71.76% and +43.73%, respectively, from the prior year.
Any recent changes to analyst estimates for TNDM should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.15% higher within the past month. TNDM is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.